Company Overview of Convergence Pharmaceuticals Limited
Convergence Pharmaceuticals Limited, a biotechnology company, engages in the development of analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded in 2010 and is based in Cambridge, United Kingdom. As of February 28, 2015, Convergence Pharmaceuticals Limited operates as a subsidiary of Biogen Inc.
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2010
Key Executives for Convergence Pharmaceuticals Limited
Head of Chemistry and Pre-Clinical Development
Head of Clinical Operations
Head of Biology and Vice President
Compensation as of Fiscal Year 2015.
Convergence Pharmaceuticals Limited Key Developments
Convergence Pharmaceuticals Limited Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Convergence Pharmaceuticals Limited Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-Breaking Phase II Trigeminal Neuralgia Study
Jun 16 14
Convergence Pharmaceuticals Holdings Limited announced positive data from the Phase II clinical trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TGN), a very severe form of facial pain. CNV1014802 is a novel small molecule state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel. Following an initial 21 day open-label treatment period with CNV1014802 at a dose of 150mg three times a day (tid), patients who showed a successful response in the final week of the period, defined as a 30% or more reduction in numbers of paroxysms, or severity of paroxysms, relative to the run-in period, were then randomised to a 28 day double-blind treatment period with either CNV1014802 150mg tid or placebo. All patients entering the study had to have a pre-specified number of paroxysmal attacks of at least moderate severity. A total of 67 patients were recruited into the study and 69% of those patients completing the open label period were randomised as clear responders into the double-blind phase of the study. The novel design of this study protocol has been published and is available online. CNV1014802 was well tolerated and the study showed a consistent reduction of pain severity and number of paroxysms in all primary and secondary outcomes. In the primary endpoint of the study there was a treatment failure rate of just 33% for CNV1014802 vs 65% for placebo and a favourable separation from placebo on the Kaplan Meier time to relapse. CNV1014802 showed a 2.3 unit decrease in the NRS scale for pain intensity, 60% reduction in paroxysms vs. 12% in placebo and pain severity dropped by 55% vs. 18% placebo, by the end of the study. There were no serious adverse events related to the drug and the adverse event profile of the drug was similar to placebo in the double blind phase of the study. The full study will be published at the International Association for the Study of Pain (IASP) World Congress of Pain, Buenos Aires in October 2014. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013 and Convergence will utilise these data to design a pivotal clinical study to start in early 2015 with a view to commercialising an orphan drug as soon as possible. This is the first well powered, randomized and placebo controlled clinical trial to demonstrate efficacy of a selective state dependent Nav1.7 inhibitor in a chronic pain indication. This follows years of intensive research and provides huge promise for a better standard of treatment for TGN in the future.
Convergence Pharmaceuticals Plans An IPO
Jun 16 14
Convergence Pharmaceuticals Limited is preparing for a possible stock market listing. Convergence Pharmaceuticals could raise £50-£100 million in the initial public offering. Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, said that listings in London and New York wre under consideration, with a potential floatation most likely to take place in early 2015. Clive Dix said, “We are now starting to talk to advisers about the state of the FTSE and Nasdaq markets for biotech and are considering seriously floating the company. We'd probably be looking to go out early next year.”
Similar Private Companies By Industry
Recent Private Companies Transactions
January 11, 2015